These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
820 related articles for article (PubMed ID: 31540840)
1. Prevalence, estimated incidence, risk behaviours, and genotypic distribution of hepatitis C virus among people who inject drugs accessing harm-reduction services in Kenya: a retrospective cohort study. Akiyama MJ; Cleland CM; Lizcano JA; Cherutich P; Kurth AE Lancet Infect Dis; 2019 Nov; 19(11):1255-1263. PubMed ID: 31540840 [TBL] [Abstract][Full Text] [Related]
2. Characteristics associated with HIV and hepatitis C seroprevalence among sexual and injecting partners of HIV positive persons who inject drugs in Nairobi and coastal Kenya. Sambai BC; Kingston H; Monroe-Wise A; Mbogo L; Juma E; Ludwig-Barron N; Guthrie BL; Bukusi D; Chohan BH; Scott J; Bosire R; Dunbar M; Macharia P; Masyuko S; Sinkele W; Herbeck JT; Farquhar C BMC Infect Dis; 2022 Jan; 22(1):73. PubMed ID: 35062890 [TBL] [Abstract][Full Text] [Related]
3. Rapid situational assessment of people who inject drugs (PWID) in Nairobi and coastal regions of Kenya: a respondent driven sampling survey. Oguya FO; Kenya PR; Ongecha F; Mureithi P; Musyoka H; Muraguri N; Mundia B; Angira C; Shose M; Basheeb TA; Mohamed AA; Oyore JP; Ochieng OG; Dida GO; Abdalla S; Abdool R BMC Public Health; 2021 Aug; 21(1):1549. PubMed ID: 34391389 [TBL] [Abstract][Full Text] [Related]
4. Widespread hepatitis C virus transmission network among people who inject drugs in Kenya. Akiyama MJ; Khudyakov Y; Ramachandran S; Riback LR; Ackerman M; Nyakowa M; Arthur L; Lizcano J; Walker J; Cherutich P; Kurth A Int J Infect Dis; 2024 Oct; 147():107215. PubMed ID: 39182826 [TBL] [Abstract][Full Text] [Related]
5. Understanding hepatitis B, hepatitis C and HIV among people who inject drugs in South Africa: findings from a three-city cross-sectional survey. Scheibe A; Young K; Moses L; Basson RL; Versfeld A; Spearman CW; Sonderup MW; Prabdial-Sing N; Manamela J; Puren AJ; Rebe K; Hausler H Harm Reduct J; 2019 Apr; 16(1):28. PubMed ID: 30975139 [TBL] [Abstract][Full Text] [Related]
6. Prevalence and risk factors associated with HIV/hepatitis B and HIV/hepatitis C co-infections among people who inject drugs in Mozambique. Semá Baltazar C; Boothe M; Kellogg T; Ricardo P; Sathane I; Fazito E; Raymond HF; Temmerman M; Luchters S BMC Public Health; 2020 Jun; 20(1):851. PubMed ID: 32493347 [TBL] [Abstract][Full Text] [Related]
7. Burden of hepatitis C virus disease and access to hepatitis C virus services in people who inject drugs in India: a cross-sectional study. Solomon SS; Mehta SH; Srikrishnan AK; Solomon S; McFall AM; Laeyendecker O; Celentano DD; Iqbal SH; Anand S; Vasudevan CK; Saravanan S; Lucas GM; Kumar MS; Sulkowski MS; Quinn TC Lancet Infect Dis; 2015 Jan; 15(1):36-45. PubMed ID: 25486851 [TBL] [Abstract][Full Text] [Related]
8. Modelling the impact of HIV and hepatitis C virus prevention and treatment interventions among people who inject drugs in Kenya. Stone J; Fraser H; Walker JG; Mafirakureva N; Mundia B; Cleland C; Bartilol K; Musyoki H; Waruiru W; Ragi A; Bhattacharjee P; Chhun N; Lizcano J; Akiyama MJ; Cherutich P; Wisse E; Kurth A; Luhmann N; Vickerman P AIDS; 2022 Dec; 36(15):2191-2201. PubMed ID: 36111533 [TBL] [Abstract][Full Text] [Related]
9. HIV Prevalence, Estimated Incidence, and Risk Behaviors Among People Who Inject Drugs in Kenya. Kurth AE; Cleland CM; Des Jarlais DC; Musyoki H; Lizcano JA; Chhun N; Cherutich P J Acquir Immune Defic Syndr; 2015 Dec; 70(4):420-7. PubMed ID: 26226249 [TBL] [Abstract][Full Text] [Related]
10. HIV, Hepatitis B and C among people who inject drugs: high prevalence of HIV and Hepatitis C RNA positive infections observed in Delhi, India. Ray Saraswati L; Sarna A; Sebastian MP; Sharma V; Madan I; Thior I; Pulerwitz J; Tun W BMC Public Health; 2015 Jul; 15():726. PubMed ID: 26223866 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of assisted partner services for people who inject drugs in Kenya to identify partners living with HIV and hepatitis C virus infection: a prospective cohort study. Monroe-Wise A; Mbogo L; Sambai B; Ludwig-Barron N; Guthrie BL; Bukusi D; Chohan BH; Masyuko S; Scott J; Juma E; Macharia P; Kingston H; Sinkele W; Gitau E; Bosire R; Musyoki H; Herbeck J; Farquhar C Lancet Glob Health; 2024 May; 12(5):e859-e867. PubMed ID: 38614633 [TBL] [Abstract][Full Text] [Related]
12. Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs. Platt L; Minozzi S; Reed J; Vickerman P; Hagan H; French C; Jordan A; Degenhardt L; Hope V; Hutchinson S; Maher L; Palmateer N; Taylor A; Bruneau J; Hickman M Cochrane Database Syst Rev; 2017 Sep; 9(9):CD012021. PubMed ID: 28922449 [TBL] [Abstract][Full Text] [Related]
13. Prevalence and associated risk factors of hepatitis C antibody and RNA among people who inject drugs in Puerto Rico. Aponte-Meléndez Y; Eckhardt B; Fong C; Padilla A; Trinidad-Martínez W; Maldonado-Rodríguez E; Agront N; Mateu-Gelabert P J Subst Use Addict Treat; 2024 May; 160():209308. PubMed ID: 38301921 [TBL] [Abstract][Full Text] [Related]
14. Hepatitis B, hepatitis C and HIV prevalence and related sexual and substance use risk practices among key populations who access HIV prevention, treatment and related services in South Africa: findings from a seven-city cross-sectional survey (2017). Scheibe A; Young K; Versfeld A; Spearman CW; Sonderup MW; Prabdial-Sing N; Puren A; Hausler H BMC Infect Dis; 2020 Sep; 20(1):655. PubMed ID: 32894072 [TBL] [Abstract][Full Text] [Related]
15. Polysubstance Use and Related Risk Behaviors among People Who Inject Drugs in Kenya Preparing for Hepatitis C Virus Treatment. Riback LR; Nyakowa M; Lizcano JA; Zhang C; Cherutich P; Kurth AE; Akiyama MJ Viruses; 2024 Aug; 16(8):. PubMed ID: 39205251 [TBL] [Abstract][Full Text] [Related]
16. Age-Related Differences in Past or Present Hepatitis C Virus Infection Among People Who Inject Drugs: National Human Immunodeficiency Virus Behavioral Surveillance, 8 US Cities, 2015. Abara WE; Trujillo L; Broz D; Finlayson T; Teshale E; Paz-Bailey G; Glick S; Al-Tayyib AA; Robinson WT; Masiello-Schuette S; Sey EK; Anderson BJ; Poe J; Braunstein S J Infect Dis; 2019 Jul; 220(3):377-385. PubMed ID: 30915477 [TBL] [Abstract][Full Text] [Related]
17. Measuring the incidence, prevalence and genetic relatedness of hepatitis C infections among a community recruited sample of injecting drug users, using dried blood spots. Hope VD; Hickman M; Ngui SL; Jones S; Telfer M; Bizzarri M; Ncube F; Parry JV J Viral Hepat; 2011 Apr; 18(4):262-70. PubMed ID: 20456636 [TBL] [Abstract][Full Text] [Related]
18. Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada. Lanièce Delaunay C; Maheu-Giroux M; Marathe G; Saeed S; Martel-Laferrière V; Cooper CL; Walmsley S; Cox J; Wong A; Klein MB; Int J Drug Policy; 2022 May; 103():103627. PubMed ID: 35218989 [TBL] [Abstract][Full Text] [Related]
19. Harm Reduction Coverage and Hepatitis C Incidence: Findings From a Cohort of People Who Inject Drugs. Minoyan N; Artenie AA; Zang G; Jutras-Aswad D; Turcotte MÈ; Bruneau J Am J Prev Med; 2020 Jun; 58(6):845-853. PubMed ID: 32444003 [TBL] [Abstract][Full Text] [Related]
20. High variability of HIV and HCV seroprevalence and risk behaviours among people who inject drugs: results from a cross-sectional study using respondent-driven sampling in eight German cities (2011-14). Wenz B; Nielsen S; Gassowski M; Santos-Hövener C; Cai W; Ross RS; Bock CT; Ratsch BA; Kücherer C; Bannert N; Bremer V; Hamouda O; Marcus U; Zimmermann R; BMC Public Health; 2016 Sep; 16(1):927. PubMed ID: 27595567 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]